The management of type 2 diabetes with fixed‐ratio combination insulin degludec/liraglutide (IDegLira) versus basal‐bolus therapy (insulin glargine U100 plus insulin aspart): A short‐term cost‐effectiveness analysis in the UK setting

AIM: To evaluate the cost‐effectiveness of IDegLira versus basal‐bolus therapy (BBT) with insulin glargine U100 plus up to 4 times daily insulin aspart for the management of type 2 diabetes in the UK. METHODS: A Microsoft Excel model was used to evaluate the cost‐utility of IDegLira versus BBT over...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Diabetes Obes Metab
Autores principales: Drummond, Russell, Malkin, Samuel, Du Preez, Michelle, Lee, Xin Ying, Hunt, Barnaby
Formato: Artigo
Lenguaje:Inglês
Publicado: Blackwell Publishing Ltd 2018
Materias:
Original Articles
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6175071/
https://ncbi.nlm.nih.gov/pubmed/29797389
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/dom.13375
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares